Elevation Oncology Inc (ELEV) concluded trading on Thursday at a closing price of $0.28, with 17.59 million shares of worth about $4.93 million changed hands on the day. Half year performance of the stock remained negative as price took a plunge of -53.94% during that period and on March 20, 2025 the price saw a loss of about -41.82%. Currently the company’s common shares owned by public are about 59.13M shares, out of which, 52.07M shares are available for trading.
Stock saw a price change of -44.23% in past 5 days and over the past one month there was a price change of -57.24%. Year-to-date (YTD), ELEV shares are showing a performance of -50.59% which decreased to -93.62% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $0.41 but also hit the highest price of $5.83 during that period. The average intraday trading volume for Elevation Oncology Inc shares is 2.22 million. The stock is currently trading -44.89% below its 20-day simple moving average (SMA20), while that difference is down -54.04% for SMA50 and it goes to -75.16% lower than SMA200.
Elevation Oncology Inc (NASDAQ: ELEV) currently have 59.13M outstanding shares and institutions hold larger chunk of about 56.02% of that.
The stock has a current market capitalization of $16.46M and its 3Y-monthly beta is at 1.41. It has posted earnings per share of -$0.80 in the same period. It has Quick Ratio of 21.21 while making debt-to-equity ratio of 0.52. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for ELEV, volatility over the week remained 13.10% while standing at 10.98% over the month.
Stock’s fiscal year EPS is expected to rise by 11.22% while it is estimated to increase by 3.87% in next year. EPS is likely to grow at an annualized rate of 1.36% for next 5-years, compared to annual growth of -25.69% made by the stock over the past 5-years.
Coverage by Piper Sandler stated Elevation Oncology Inc (ELEV) stock as an Overweight in their note to investors on May 31, 2024, suggesting a price target of $10 for the stock. On May 14, 2024, Stephens Initiated their recommendations, while on March 01, 2024, JMP Securities Initiated their ratings for the stock with a price target of $7. Stock get an Outperform rating from SVB Securities on May 30, 2023.
